Dogwood Therapeutics (DWTX) risk factors, FY2025 10-K

Dogwood Therapeutics's FY2025 10-K, filed Mar 18, 2026, lists 60 risk factors in 9 groups. Against the prior year's 66: 6 new, 12 dropped, 16 substantially reworded.

Open DWTX in Gloom →
Dogwood Therapeutics' chart, financials and news, free in your browser.Open DWTX in Gloom →
Risk factors listed
609 groups
New this year
6vs 66 last year
Dropped
12since the prior 10-K
Substantially reworded
16of those kept
Section length
26k wordsItem 1A

What the changes say

  • Dogwood Therapeutics shifted its active development pipeline from IMC-1 and IMC-2 to SP16 alongside Halneuron.
  • The company received a Nasdaq delisting notice for trading below $1.00 per share and dropped several recent combination transaction risks.

What changed since the prior 10-K

New

  • NewRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    Government investigations of alleged violations could require significant resources and generate negative publicity. Any sanctions or loss of approval would adversely affect commercialization and revenue generation, and materially harm our business

    Government investigations, regulatory changes, infectious disease disruptions, or compliance failures could harm our business and commercialization.

  • NewRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    o if FDA determines that our labeling is false or misleading in any particular way

    The FDA or foreign agencies may approve our drugs for limited indications, require strict safety labeling, or reject our applications entirely.

  • NewRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    Even if we obtain FDA approval for Halneuron ® , SP16 or any other product candidate we develop in the future in the United States, we may never obtain approval for or commercialize those product candidates in any other jurisdiction, which would limit our ability to realize their full global market potential

    Obtaining FDA approval for Halneuron or SP16 does not guarantee approval in foreign jurisdictions, limiting our global market potential.

  • NewRisks Related to Commercialization

    Our products may be subject to certain legal and regulatory requirements regarding the packaging, distribution, sale, and labeling of medical products in the United States

    Federal and state consumer protection, packaging, and distribution laws apply to our medical products.

  • NewRisks Related to Commercialization

    The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products

    Failure to meet strict pharmaceutical distribution, licensing, and record-keeping rules can result in criminal prosecution, fines, or product seizures.

  • NewRisks Related to Our Dependence on Third Parties

    can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects

    Disruptions in our collaborations could delay product development and reduce our funding.

Dropped

  • DroppedRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for Halneuron®, IMC-1, IMC-2 or any other product candidates, our business will be substantially harmed

  • DroppedRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly

  • DroppedRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business

  • DroppedRisks Related to Our Intellectual Property

    relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates

  • DroppedRisks Related to Our Common Stock

    pursuant to the General Corporation Law of the State of Delaware, our certificate of incorporation, or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine

  • DroppedRisks Related to the Combination

    There is no guarantee that the Combination will increase stockholder value

  • DroppedRisks Related to the Combination

    Tetrodotoxin and Halneuron® may become subject to a contractual repurchase right in certain circumstances, which could have a material adverse effect on our results of operations, financial condition, and cash flows

  • DroppedRisks Related to the Combination

    Pursuant to the terms of the Exchange Agreement, we are required to recommend that our stockholders approve the conversion of all outstanding shares of our Series A Non-Voting Convertible Preferred Stock into shares of our Common Stock. We cannot guarantee that our stockholders will approve this matter

  • DroppedRisks Related to the Combination

    The issuance of common stock upon conversion of our outstanding Series A Non-Voting Convertible Preferred Stock and Series A-1 Non-Voting Convertible Preferred Stock will cause immediate and substantial dilution to existing shareholders

    Lengthy FDA and foreign regulatory approval processes for Halneuron, IMC-1, or IMC-2.

  • DroppedRisks Related to the Combination

    We may be required to settle shares of Series A Non-Voting Convertible Preferred Stock for cash, which could have a material adverse effect on our business and financial condition

  • DroppedRisks Related to the Combination

    The failure to successfully integrate the businesses of the Company and Pharmagesic in the expected timeframe could adversely affect Dogwood’s results of operations, financial condition, and future results

  • DroppedRisks Related to the Combination

    We expect to incur substantial expenses related to the integration of Pharmagesic

    Undesirable side effects of product candidates causing patient injury or death.

Reworded

  • 93% rewrittenRisks Related to Our Common Stock

    If we are unable to maintain listing of our common stock on the Nasdaq Capital Market or another national stock exchange, it may be more difficult for our stockholders to sell their shares of common stock

    Updated from a stockholders' equity deficiency notice to a Nasdaq delisting notice for a bid price below $1.00 for 30 consecutive business days.

  • 89% rewrittenRisks Related to Our Common Stock

    Our certificate of incorporation and our bylaws will contain exclusive forum provisions for certain claims, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees

    Added explicit references to the General Corporation Law of the State of Delaware and the internal affairs doctrine for exclusive forum provisions.

  • 80% rewrittenRisks Related to Our Common Stock

    We are a “smaller reporting company” and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors

    Updated to reflect that the company no longer qualifies as an emerging growth company but still qualifies as a smaller reporting company.

    Was: We are an “emerging growth company,” and a “smaller reporting company” and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors

  • 69% rewrittenRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    We are heavily dependent on the success of our product candidates which are still under clinical development, and if these candidates do not receive regulatory approval or, if approved, our commercialization efforts are unsuccessful, our business may be harmed

    Replaced product candidates IMC-1 for fibromyalgia and IMC-2 for long COVID with SP16 for neuropathy and nerve damage under active development.

    Was: We are heavily dependent on the success of our product candidates, Halneuron®, IMC-1 and IMC-2, which are still under clinical development, and if these candidates do not receive regulatory approval or, if approved, our commercialization efforts are unsuccessful, our business may be harmed

  • 65% rewrittenRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    Clinical trials are expensive, time-consuming and difficult to design and implement and involve an uncertain outcome

    Removed specific product names Halneuron, IMC-1, and IMC-2, generalizing the risk to all product candidates.

  • 50% rewrittenRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials

    No substantive textual changes made to the risk description.

  • 50% rewrittenRisks Related to Our Dependence on Third Parties

    We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business

    No substantive textual changes made to the risk description.

  • 45% rewrittenRisks Related to Our Intellectual Property

    We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates

    No substantive textual changes made to the risk description.

  • 44% rewrittenRisks Related to Healthcare Laws and Other Legal Compliance Matters

    If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations

  • 36% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

    We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates

    Was: We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of Halneuron®, IMC-1 or IMC-2

  • 32% rewrittenRisks Related to Commercialization

    We may face early generic competition for Halneuron ® , SP16 or any other products we successfully develop and market

    Was: We may face early generic competition for Halneuron®, IMC-1, IMC-2 or any other products we successfully develop and market

  • 32% rewrittenRisks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

    The market opportunities for Halneuron ® and/or SP16, if approved, may be smaller than we anticipate

    Was: The market opportunities for Halneuron®, IMC-1 or IMC-2, if approved, may be smaller than we anticipate

  • 31% rewrittenRisks Related to Our Intellectual Property

    We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms

  • 30% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

    Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations

  • 22% rewrittenRisks Related to the Combination

    If our acquired intangible assets and goodwill become impaired, we may be required to record a significant charge to earnings

  • 22% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

    We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability

All 60 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Position and Need for Additional Capital

  1. 01We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability22% rewritten
  2. 02We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates36% rewritten
  3. 03Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
  4. 04Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations30% rewritten
  5. 05We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability

Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

  1. 06We are heavily dependent on the success of our product candidates which are still under clinical development, and if these candidates do not receive regulatory approval or, if approved, our commercialization efforts are unsuccessful, our business may be harmed69% rewritten
  2. 07Government investigations of alleged violations could require significant resources and generate negative publicity. Any sanctions or loss of approval would adversely affect commercialization and revenue generation, and materially harm our businessNew
  3. 08The development of our product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease
  4. 09Clinical trials are expensive, time-consuming and difficult to design and implement and involve an uncertain outcome65% rewritten
  5. 10o if FDA determines that our labeling is false or misleading in any particular wayNew
  6. 11Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control
  7. 12Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials50% rewritten
  8. 13The market opportunities for Halneuron ® and/or SP16, if approved, may be smaller than we anticipate32% rewritten
  9. 14We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates
  10. 15Even if we obtain FDA approval for Halneuron ® , SP16 or any other product candidate we develop in the future in the United States, we may never obtain approval for or commercialize those product candidates in any other jurisdiction, which would limit our ability to realize their full global market potentialNew
  11. 16Even if we obtain regulatory approval for Halneuron ® , SP16 or any other product candidate we develop in the future, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties
  12. 17We may seek a Breakthrough Therapy designation for Halneuron ® from the FDA. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process
  13. 18Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop

Risks Related to Commercialization

  1. 19We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively
  2. 20Our products may be subject to certain legal and regulatory requirements regarding the packaging, distribution, sale, and labeling of medical products in the United StatesNew
  3. 21The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical productsNew
  4. 22We may face early generic competition for Halneuron ® , SP16 or any other products we successfully develop and market32% rewritten
  5. 23Even if any of our product candidates we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success
  6. 24If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate that receives regulatory approval
  7. 25A variety of risks associated with operating internationally could materially adversely affect our business

Risks Related to Our Dependence on Third Parties

  1. 26We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business50% rewritten
  2. 27can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospectsNew

Risks Related to Healthcare Laws and Other Legal Compliance Matters

  1. 28Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set
  2. 29Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
  3. 30Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation
  4. 31We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities
  5. 32If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations44% rewritten

Risks Related to Our Intellectual Property

  1. 33Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours
  2. 34We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates45% rewritten
  3. 35Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
  4. 36Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
  5. 37We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
  6. 38If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed
  7. 39Intellectual property rights do not address all potential threats to our competitive advantage
  8. 40If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
  9. 41We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms31% rewritten
  10. 42We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties
  11. 43Our proprietary information may be lost, or we may suffer security breaches

Risks Related to Our Employees, Managing Our Growth and Our Operations

  1. 44Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
  2. 45We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
  3. 46We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources
  4. 47Our business and operations would suffer in the event of system failures
  5. 48We may be materially adversely affected by currency fluctuations in the United States dollar versus the Canadian dollar

Risks Related to Our Common Stock

  1. 49If we are unable to maintain listing of our common stock on the Nasdaq Capital Market or another national stock exchange, it may be more difficult for our stockholders to sell their shares of common stock93% rewritten
  2. 50The market price of our common stock is highly volatile, which could result in substantial losses for holders of our common stock
  3. 51We could be subject to securities class action litigation
  4. 52If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline
  5. 53We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
  6. 54We are subject to significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
  7. 55If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
  8. 56We are a “smaller reporting company” and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors80% rewritten
  9. 57Provisions in our certificate of incorporation and bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
  10. 58Our certificate of incorporation and our bylaws will contain exclusive forum provisions for certain claims, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees89% rewritten

Risks Related to the Combination

  1. 59If our acquired intangible assets and goodwill become impaired, we may be required to record a significant charge to earnings22% rewritten
  2. 60Our future results will suffer if we do not effectively manage our expanded operations

Other Dogwood Therapeutics 10-Ks

  • FY2024 10-K risk factors
    66 risks

    Development-stage biotech facing ongoing net losses, significant accumulated deficit, and heavy reliance on capital raises to fund trials.

    Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.